Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;598(3):429-430.
doi: 10.1113/JP279267. Epub 2020 Jan 16.

Suppressing 'nonsense' in cystic fibrosis

Alexandre Hinzpeter  1   2 , Isabelle Sermet-Gaudelus  1   2 , David N Sheppard  3
Affiliations
Comment

Suppressing 'nonsense' in cystic fibrosis

Alexandre Hinzpeter et al. J Physiol. 2020 Feb.
No abstract available

Keywords: CFTR; CFTR correctors and potentiators; cystic fibrosis; premature termination codons (PTCs).

PubMed Disclaimer

Comment on

References

    1. Carroll TP, Morales MM, Fulmer SB, Allen SS, Flotte TR, Cutting GR & Guggino WB (1995). Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem 270, 11941-11946.
    1. Haggie PM, Phuan PW, Tan JA, Xu H, Avramescu RG, Perdomo D, Zlock L, Nielson DW, Finkbeiner WE, Lukacs GL & Verkman AS (2017). Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane regulator (CFTR) translation product. J Biol Chem 292, 771-785.
    1. Howard M, Frizzell RA & Bedwell DM (1996). Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2, 467-469.
    1. Laselva O, Eckford PD, Bartlett C, Ouyang H, Gunawardena TN, Gonska T, Moraes TJ, Bear CE (2019). Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action. J Cyst Fibros (in press; https://doi.org/10.1016/j.jcf.2019.12.001.
    1. Sharma N, Evans TA, Pellicore MJ, Davis E, Aksit MA, McCague AF, Joynt AT, Lu Z, Han ST, Anzmann AF, Lam AN, Thaxton A, West N, Merlo C, Gottschalk LB, Raraigh KS, Sosnay PR, Cotton CU & Cutting GR (2018). Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis. PLoS Genet 14, e1007723.

Publication types